AR110051A2 - Pirazolo[3,4-d]pirimidinas útiles para tratar trastornos respiratorios - Google Patents
Pirazolo[3,4-d]pirimidinas útiles para tratar trastornos respiratoriosInfo
- Publication number
- AR110051A2 AR110051A2 ARP170103136A ARP170103136A AR110051A2 AR 110051 A2 AR110051 A2 AR 110051A2 AR P170103136 A ARP170103136 A AR P170103136A AR P170103136 A ARP170103136 A AR P170103136A AR 110051 A2 AR110051 A2 AR 110051A2
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- amino
- carbonyl
- sulfonyl
- alkoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicación 1: El uso de un compuesto de la fórmula (1), o una sal, adecuadamente una sal farmacéuticamente aceptable, o un solvato del mismo, en donde: R¹ es alquilo C₁₋₃, opcionalmente sustituido por 1 a 7 grupos flúor; R² es un grupo heteroarilo de 5 a 6 miembros, ó R² es fenilo que tiene el patrón de sustitución, de fórmula (2), en donde el grupo heteroarilo de 5 a 6 miembros está opcionalmente fusionado por fenilo, un grupo heteroarilo de 5 a 6 miembros adicional, un grupo carbocíclico C₄₋₆, o un grupo heterociclilo de 5 a 6 miembros, y en donde el fenilo R² está opcionalmente fusionado en R⁴ - R⁵, R⁵ - R⁶, R⁶ - R⁷, ó R⁷ - R⁸ por un fenilo adicional, un grupo heteroarilo de 5 a 6 miembros, miembros o el heteroarilo de 5 a 6 miembros fusionado, el fenilo o el grupo fenilo fusionado, está independientemente opcionalmente sustituido por uno o más grupos seleccionados a partir de la Lista X; la Lista X representa hidroxilo, ciano, nitro, alquilo C₁₋₈, alquenilo C₁₋₈, alquinilo C₁₋₈, alcoxilo C₁₋₈, alqueniloxilo C₁₋₈, alquiniloxilo C₁₋₈, fenilo, un grupo heteroarilo de 5 a 6 miembros, un grupo carbocíclico C₄₋₆, o un grupo heterociclilo de 5 a 6 miembros, -(alquileno C₀₋₄)-O-(alquileno C₁₋₄)-R⁹, (alquileno C₀₋₄)-O-(alquileno C₂₋₄)-R¹⁰, (alquileno C₀₋₄)-N(R¹¹)-(alquileno C₁₋₄)-R¹², -(alquileno C₀₋₄)-N(R¹³)-(alquileno C₂₋₄)-R¹⁴, halógeno, formilo, alquilo C₁₋₈-carbonilo, carboxilo, alcoxilo C₁₋₈-carbonilo, alquilo C₁₋₈-amino-oxi-carbonilo, di-alquilo C₁₋₈-amino-oxi-carbonilo, amino, alquilo C₁₋₈-amino, di-alquilo C₁₋₈-amino, alquilo C₁₋₈-amidino, -N(H)C(=NH)-alquilo C₁₋₈, -N(alquilo C₁₋₈)C(=NH)-alquilo C₁₋₈, alquilo C₁₋₈-amino-carbonilo, di-alquilo C₁₋₈-amino-carbonilo, amino-carbonil-amino, amino-carbonil-(alquilo C₁₋₈)-amino, alquilo C₁₋₈-amino-carbonil-amino, di-alquilo C₁₋₈-amino-carbonil-amino, alquilo C₁₋₈-amino-carbonil-(alquilo C₁₋₈)-amino, di-alquilo C₁₋₈-amino-carbonil-(alquilo C₁₋₈)-amino, alquilo C₁₋₈-carbonil-amino, alquilo C₁₋₈-carbonil-(alquilo C₁₋₈)-amino, alquilo C₁₋₈-tiocarbonil-amino, alquilo C₁₋₈-tiocarbonil-(alquilo C₁₋₈)-amino, hidroxi-sulfonilo, alquilo C₁₋₈-sulfonil-amino, tioalquilo C₁₋₈, alquilo C₁₋₈-sulfinilo, alquilo C₁₋₈-sulfonilo, amino-sulfonilo, alquilo C₁₋₈-amino-sulfonilo, ó di-alquilo C₁₋₈-amino-sulfonilo, en donde cada uno de los grupos hidrocarburo anteriormente mencionados puede estar opcionalmente sustituido, donde sea químicamente factible, por uno o más grupos halógeno, hidroxilo, amino, alquilo C₁₋₄-amino, di-alquilo C₁₋₄-amino, ó alcoxilo C₁₋₄, y en donde estos grupos cíclicos pueden estar opcionalmente sustituidos por uno o más grupos hidroxilo, ciano, nitro, alquilo C₁₋₈, alquenilo C₁₋₈, alquinilo C₁₋₈, alcoxilo C₁₋₈, alqueniloxilo C₁₋₈, alquiniloxilo C₁₋₈, halógeno, alquilo C₁₋₈-carbonilo, carboxilo, alcoxilo C₁₋₈-carbonilo, amino, alquilo C₁₋₈-amino, di-alquilo C₁₋₈-amino, alquilo C₁₋₈-amino-carbonilo, di-alquilo C₁₋₈-amino-carbonilo, alquilo C₁₋₈-carbonil-amino, alquilo C₁₋₈-carbonil-(alquilo C₁₋₈)-amino, alquilo C₁₋₈-sulfonil-amino, tioalquilo C₁₋₈, alquilo C₁₋₈-sulfinilo, alquilo C₁₋₈-sulfonilo, amino-sulfonilo, alquilo C₁₋₈-amino-sulfonilo, ó di-alquilo C₁₋₈-amino-sulfonilo; R⁹ y R¹² representan independientemente hidrógeno, alquenilo C₁₋₄, alquinilo C₁₋₄, halógeno, ciano, nitro, alquilo C₁₋₈-carbonilo, carboxilo, alcoxilo C₁₋₈-carbonilo, tioalquilo C₁₋₈, alquilo C₁₋₈-sulfinilo, alquilo C₁₋₈-sulfonilo, amino-sulfonilo, alquilo C₁₋₈-amino-sulfonilo, di-alquilo C₁₋₈-amino-sulfonilo, fenilo, un grupo heteroarilo, de 5 a 6 miembros C-enlazado, un grupo carbocíclico o un grupo heterociclilo de 5 a 6 miembros C-enlazado, en donde este fenilo o los grupos cíclicos pueden estar opcionalmente sustituidos por uno o más grupos hidroxilo, ciano, nitro, alquilo C₁₋₈, alquenilo C₁₋₈, alquinilo C₁₋₈, alcoxilo C₁₋₈, alqueniloxilo C₁₋₈, alquiniloxilo C₁₋₈, halógeno, alquilo C₁₋₈-carbonilo, carboxilo, alcoxilo C₁₋₈-carbonilo, amino, alquilo C₁₋₈-amino, di-alquilo C₁₋₈-amino, alquilo C₁₋₈-amino-carbonilo, di-alquilo C₁₋₈-amino-carbonilo, alquilo C₁₋₈-carbonil-amino, alquilo C₁₋₈-carbonil-(alquilo C₁₋₈)-amino, alquilo C₁₋₈-sulfonil-amino, tioalquilo C₁₋₈, alquilo C₁₋₈-sulfonilo, alquilo C₁₋₈-sulfonilo, amino-sulfonilo, alquilo C₁₋₈-amino-sulfonilo, ó di-alquilo C₁₋₈-amino-sulfonilo; R¹⁰ y R¹⁴ representan independientemente hidroxilo, alcoxilo C₁₋₄, alqueniloxilo C₁₋₄, alquiniloxilo C₁₋₄, amino, alquilo C₁₋₈-amino, di-alquilo C₁₋₈-amino, alquilo C₁₋₈-amino-carbonilo, di-alquilo C₁₋₈-amino-carbonilo, alquilo C₁₋₈-carbonil-amino, alquilo C₁₋₈-carbonil-(alquilo C₁₋₈)-amino, alquilo C₁₋₈-sulfonil-amino, un grupo heteroarilo de 5 a 6 miembros N-enlazado, o un grupo heterociclilo de 5 a 6 miembros N-enlazado, en donde estos grupos cíclicos pueden estar opcionalmente sustituidos por uno o más grupos hidroxilo, nitro, alquilo C₁₋₈, alquenilo C₁₋₈, alquinilo C₁₋₈, alcoxilo C₁₋₈, alqueniloxilo C₁₋₈, alquiniloxilo C₁₋₈, halógeno, alquilo C₁₋₈-carbonilo, carboxilo, alcoxilo C₁₋₈-carbonilo, amino, alquilo C₁₋₈-amino, di-alquilo C₁₋₈-amino, alquilo C₁₋₈-amino-carbonilo, di-alquilo C₁₋₈-amino-carbonilo, alquilo C₁₋₈-carbonil-amino, alquilo C₁₋₈-carbonil-(alquilo C₁₋₈)-amino, alquilo C₁₋₈-sulfonil-amino, tioalquilo C₁₋₈, alquilo C₁₋₈-sulfinilo, alquilo C₁₋₈-sulfonilo, amino-sulfonilo, alquilo C₁₋₈-amino-sulfonilo, ó di-alquilo C₁₋₈-amino-sulfonilo; R¹¹ y R¹³ representan independientemente hidrógeno o alquilo C₁₋₆; R³ es hidrógeno, amino, o alquilo C₁₋₃-amino; Y representa hidrógeno, alquilo C₁₋₈, alcoxilo C₁₋₈, en donde cada uno de los grupos hidrocarburo anteriormente mencionados puede estar opcionalmente sustituido, donde sea químicamente factible, por uno o más grupos halógeno, hidroxilo, amino, alquilo C₁₋₈-amino, di-alquilo C₁₋₈-amino, o alcoxilo C₁₋₈, ó Y representa el grupo (alquileno C₀₋₄)-N(R¹⁵)R¹⁶; y R¹⁵ y R¹⁶ representan independientemente hidrógeno o alquilo C₁₋₄, o R¹⁵ es hidrógeno y R¹⁶ es alquilo C₁₋₄ sustituido por fenilo, un grupo heteroarilo de 5 a 6 miembros, un grupo carbocíclico C₄₋₆, o un grupo heterociclilo de 5 a 6 miembros, en donde estos anillos están opcionalmente sustituidos por uno o más grupos hidroxilo, nitro, alquilo C₁₋₈, alquenilo C₁₋₈, alquinilo C₁₋₈, alcoxilo C₁₋₈, alqueniloxilo C₁₋₈, alquiniloxilo C₁₋₈, halógeno, alquilo C₁₋₈-carbonilo, carboxilo, alcoxilo C₁₋₈-carbonilo, amino, alquilo C₁₋₈-amino, di-alquilo C₁₋₈-amino, alquilo C₁₋₈-amino-carbonilo, di-alquilo C₁₋₈-amino-carbonilo, alquilo C₁₋₈-carbonil-amino, alquilo C₁₋₈-carbonil-(alquilo C₁₋₈)-amino, alquilo C₁₋₈-sulfonil-amino, tioalquilo C₁₋₈, alquilo C₁₋₈-sulfinilo, alquilo C₁₋₈-sulfonilo, amino-sulfonilo, alquilo C₁₋₈-amino-sulfonilo, ó di-alquilo C₁₋₈-amino-sulfonilo, en donde cada uno de los grupos hidrocarburo anteriormente mencionados puede estar opcionalmente sustituido, donde sea químicamente factible, por uno o más grupos halógeno, hidroxilo, amino, alquilo C₁₋₄-amino, di-alquilo C₁₋₄-amino, ó alcoxilo C₁₋₄, ó R¹⁵ y R¹⁶ junto con el N con el que están unidos, forman un anillo heterocíclico de 5 a 6 miembros; en el tratamiento de un trastorno respiratorio.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0610242.0A GB0610242D0 (en) | 2006-05-23 | 2006-05-23 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR110051A2 true AR110051A2 (es) | 2019-02-20 |
Family
ID=36687588
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070102192A AR061057A1 (es) | 2006-05-23 | 2007-05-21 | Derivados de pirazolo(3,4-d)pirimidina utiles para desordenes respiratorios |
ARP170103136A AR110051A2 (es) | 2006-05-23 | 2017-11-10 | Pirazolo[3,4-d]pirimidinas útiles para tratar trastornos respiratorios |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070102192A AR061057A1 (es) | 2006-05-23 | 2007-05-21 | Derivados de pirazolo(3,4-d)pirimidina utiles para desordenes respiratorios |
Country Status (24)
Country | Link |
---|---|
US (5) | US20090131457A1 (es) |
EP (1) | EP2026811A1 (es) |
JP (1) | JP2009537580A (es) |
KR (1) | KR101106853B1 (es) |
CN (1) | CN101443013A (es) |
AR (2) | AR061057A1 (es) |
AU (1) | AU2007253615B2 (es) |
BR (1) | BRPI0712022A2 (es) |
CA (1) | CA2650661A1 (es) |
CL (1) | CL2007001455A1 (es) |
CR (1) | CR10419A (es) |
EC (1) | ECSP088902A (es) |
GB (1) | GB0610242D0 (es) |
GT (1) | GT200800256A (es) |
IL (1) | IL195017A0 (es) |
MA (1) | MA30433B1 (es) |
MX (1) | MX2008014835A (es) |
NO (1) | NO20084997L (es) |
PE (1) | PE20080315A1 (es) |
RU (1) | RU2008150619A (es) |
TN (1) | TNSN08478A1 (es) |
TW (1) | TW200806665A (es) |
WO (1) | WO2007134828A1 (es) |
ZA (1) | ZA200809097B (es) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1831225A2 (en) | 2004-11-19 | 2007-09-12 | The Regents of the University of California | Anti-inflammatory pyrazolopyrimidines |
KR20150038395A (ko) | 2006-04-04 | 2015-04-08 | 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 | 키나제 길항물질 |
EA201000104A1 (ru) * | 2007-07-26 | 2010-08-30 | Новартис Аг | Производные пиримидина, применимые для лечения воспалительных или аллергических патологических состояний |
WO2009017822A2 (en) | 2007-08-02 | 2009-02-05 | Amgen Inc. | Pi3 kinase modulators and methods of use |
GB2467670B (en) | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
JP5520831B2 (ja) | 2007-12-19 | 2014-06-11 | アムジエン・インコーポレーテツド | Pi3キナーゼの阻害薬 |
EP3613743B1 (en) | 2008-01-04 | 2022-03-16 | Intellikine, LLC | Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
WO2009114870A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Kinase inhibitors and methods of use |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
EP2111861A1 (en) * | 2008-04-21 | 2009-10-28 | Ranbaxy Laboratories Limited | Compositions of phosphodiesterase type IV inhibitors |
CA2725014C (en) | 2008-05-30 | 2014-06-17 | Amgen Inc. | Inhibitors of pi3 kinase |
WO2010006072A2 (en) | 2008-07-08 | 2010-01-14 | The Regents Of The University Of California | Mtor modulators and uses thereof |
CA2730106A1 (en) | 2008-07-08 | 2010-01-14 | Intellikine, Inc. | Kinase inhibitors and methods of use |
US8220787B2 (en) * | 2008-09-19 | 2012-07-17 | Panasonic Corporation | Part mounting device |
EP2346508B1 (en) | 2008-09-26 | 2016-08-24 | Intellikine, LLC | Heterocyclic kinase inhibitors |
ES2570429T3 (es) | 2008-10-16 | 2016-05-18 | Univ California | Inhibidores de heteroaril quinasa de anillo condensado |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
TW201100427A (en) | 2009-03-31 | 2011-01-01 | Arqule Inc | Substituted heterocyclic compounds |
CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
WO2011041634A1 (en) * | 2009-10-02 | 2011-04-07 | Vertex Pharmaceuticals Incorporated | Pyrazole inhibitors of phosphatidylinositol 3-kinase |
WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
GB201004311D0 (en) | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
EP2571361A4 (en) * | 2010-05-19 | 2013-11-13 | Univ North Carolina | PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
JP5951600B2 (ja) | 2010-05-21 | 2016-07-13 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | キナーゼ調節のための、化合物、組成物および方法 |
US8901133B2 (en) | 2010-11-10 | 2014-12-02 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
TWI659956B (zh) | 2011-01-10 | 2019-05-21 | 美商英菲尼提製藥股份有限公司 | 製備異喹啉酮之方法及異喹啉酮之固體形式 |
US8362023B2 (en) | 2011-01-19 | 2013-01-29 | Hoffmann-La Roche Inc. | Pyrazolo pyrimidines |
CN106619647A (zh) | 2011-02-23 | 2017-05-10 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
CN103930422A (zh) | 2011-07-19 | 2014-07-16 | 无限药品股份有限公司 | 杂环化合物及其用途 |
WO2013012918A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
CA2846431A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
EP2751112B1 (en) | 2011-09-02 | 2019-10-09 | The Regents of The University of California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
GB201115853D0 (en) | 2011-09-14 | 2011-10-26 | Proximagen Ltd | New enzyme inhibitor compounds |
BR112014005793A2 (pt) | 2011-09-14 | 2017-03-28 | Proximagen Ltd | compostos inibidores de enzimas |
CA2850617A1 (en) | 2011-10-03 | 2013-04-11 | The University Of North Carolina At Chapel Hill | Pyrrolopyrimidine compounds for the treatment of cancer |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN104302627A (zh) | 2012-05-22 | 2015-01-21 | 北卡罗来纳大学教堂山分校 | 用于治疗癌症的嘧啶化合物 |
EP2852661A1 (en) | 2012-05-23 | 2015-04-01 | F. Hoffmann-La Roche AG | Compositions and methods of obtaining and using endoderm and hepatocyte cells |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
KR20150061651A (ko) | 2012-09-26 | 2015-06-04 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ire1의 조절 |
US9562047B2 (en) | 2012-10-17 | 2017-02-07 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
EP2925752A4 (en) | 2012-11-27 | 2016-06-01 | Univ North Carolina | PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
JP6360881B2 (ja) | 2013-03-22 | 2018-07-18 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | 触媒的mtorc1/2阻害薬及びオーロラaキナーゼの選択的阻害薬の組合せ |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
SG11201602445SA (en) | 2013-10-04 | 2016-04-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
WO2015143012A1 (en) | 2014-03-19 | 2015-09-24 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
WO2015157122A1 (en) | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Mertk-specific pyrazolopyrimidine compounds |
US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
CZ308056B6 (cs) * | 2015-07-20 | 2019-11-27 | Ustav Experimentalni Botaniky Av Cr V V I | 5-Substituované-7-[4-(substituované)benzyl]amino-3-isopropylpyrazolo[4,3-d]pyrimidiny, jejich použití jako antirevmatika, a farmaceutické přípravky |
NZ740616A (en) | 2015-09-14 | 2023-05-26 | Infinity Pharmaceuticals Inc | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
RS63609B1 (sr) | 2016-04-15 | 2022-10-31 | Cancer Research Tech Ltd | Heterociklična jedinjenja kao inhibitori ret kinaze |
RU2742115C2 (ru) | 2016-04-15 | 2021-02-02 | Кэнсер Рисерч Текнолоджи Лимитед | Гетероциклические соединения в качестве ингибиторов киназы RET |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
BR112018077021A2 (pt) | 2016-06-24 | 2019-04-02 | Infinity Pharmaceuticals, Inc. | terapias de combinação |
JOP20180009A1 (ar) * | 2017-02-06 | 2019-01-30 | Gilead Sciences Inc | مركبات مثبط فيروس hiv |
GB201705971D0 (en) | 2017-04-13 | 2017-05-31 | Cancer Res Tech Ltd | Inhibitor compounds |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR205429A1 (es) * | 1971-04-27 | 1976-05-07 | Ciba Geigy Ag | Procedimiento para la elaboracion de nuevos derivados de 4-amino - 3-(5-nitro- 2 -furil)-1-metil - 1h - pirazol-(3,4-ol)-pirimidina |
AR205234A1 (es) * | 1974-05-13 | 1976-04-12 | Lilly Co Eli | Procedimiento p a r a preparar compuestos de 3-(5-nitroimidazol-2-il) pirazolo (3,4-d) pirimidina |
US4044130A (en) * | 1974-07-03 | 1977-08-23 | Ciba-Geigy Corporation | Compositions for the control of microorganisms |
JPS5195094A (en) * | 1975-01-31 | 1976-08-20 | * ***** ****so*shi***** *o*u****** ********ne***u**** *** *** ****ne*** *************te***ku** | |
CA2376210A1 (en) * | 1999-06-08 | 2000-12-14 | Lorantis Limited | Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway |
CZ2002936A3 (cs) * | 1999-09-17 | 2002-10-16 | Abbott Gmbh & Co. Kg | Pyrazolopyrimidiny jako terapeutické prostředky |
IL152275A0 (en) * | 2000-04-25 | 2003-05-29 | Icos Corp | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
WO2003029209A2 (en) * | 2001-10-02 | 2003-04-10 | Smithkline Beecham Corporation | Chemical compounds |
AU2003225933A1 (en) * | 2002-03-22 | 2003-10-13 | Cellular Genomics, Inc. | AN IMPROVED FORMULATION OF CERTAIN PYRAZOLO(3,4-d) PYRIMIDINES AS KINASE MODULATORS |
US7429596B2 (en) * | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
EP1730148A4 (en) * | 2004-02-03 | 2009-08-19 | Abbott Lab | USE OF AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS |
EP1831225A2 (en) * | 2004-11-19 | 2007-09-12 | The Regents of the University of California | Anti-inflammatory pyrazolopyrimidines |
EA200870385A1 (ru) * | 2006-03-29 | 2009-04-28 | Фолдркс Фармасьютикалз, Инк. | Ингибирование токсичности альфа-синуклеина |
-
2006
- 2006-05-23 GB GBGB0610242.0A patent/GB0610242D0/en active Pending
-
2007
- 2007-05-21 PE PE2007000620A patent/PE20080315A1/es not_active Application Discontinuation
- 2007-05-21 CN CNA2007800173225A patent/CN101443013A/zh active Pending
- 2007-05-21 BR BRPI0712022-2A patent/BRPI0712022A2/pt not_active Application Discontinuation
- 2007-05-21 WO PCT/EP2007/004501 patent/WO2007134828A1/en active Application Filing
- 2007-05-21 AR ARP070102192A patent/AR061057A1/es not_active Application Discontinuation
- 2007-05-21 US US12/227,314 patent/US20090131457A1/en not_active Abandoned
- 2007-05-21 JP JP2009511393A patent/JP2009537580A/ja active Pending
- 2007-05-21 AU AU2007253615A patent/AU2007253615B2/en not_active Ceased
- 2007-05-21 EP EP07725407A patent/EP2026811A1/en not_active Withdrawn
- 2007-05-21 KR KR1020087028535A patent/KR101106853B1/ko active IP Right Grant
- 2007-05-21 MX MX2008014835A patent/MX2008014835A/es not_active Application Discontinuation
- 2007-05-21 RU RU2008150619/04A patent/RU2008150619A/ru not_active Application Discontinuation
- 2007-05-21 CA CA002650661A patent/CA2650661A1/en not_active Abandoned
- 2007-05-22 TW TW096118225A patent/TW200806665A/zh unknown
- 2007-05-22 CL CL200701455A patent/CL2007001455A1/es unknown
-
2008
- 2008-10-23 ZA ZA200809097A patent/ZA200809097B/xx unknown
- 2008-10-30 IL IL195017A patent/IL195017A0/en unknown
- 2008-10-30 CR CR10419A patent/CR10419A/es not_active Application Discontinuation
- 2008-11-21 GT GT200800256A patent/GT200800256A/es unknown
- 2008-11-21 TN TNP2008000478A patent/TNSN08478A1/en unknown
- 2008-11-21 EC EC2008008902A patent/ECSP088902A/es unknown
- 2008-11-26 MA MA31421A patent/MA30433B1/fr unknown
- 2008-11-28 NO NO20084997A patent/NO20084997L/no not_active Application Discontinuation
-
2013
- 2013-10-09 US US14/049,706 patent/US20140051698A1/en not_active Abandoned
-
2014
- 2014-04-25 US US14/261,890 patent/US8901134B2/en active Active
-
2016
- 2016-06-27 US US15/194,373 patent/US20160303132A1/en not_active Abandoned
-
2017
- 2017-11-10 AR ARP170103136A patent/AR110051A2/es unknown
-
2018
- 2018-01-10 US US15/867,425 patent/US20180125849A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TNSN08478A1 (en) | 2010-04-14 |
GB0610242D0 (en) | 2006-07-05 |
TW200806665A (en) | 2008-02-01 |
CR10419A (es) | 2011-07-19 |
US20090131457A1 (en) | 2009-05-21 |
GT200800256A (es) | 2009-05-28 |
US20160303132A1 (en) | 2016-10-20 |
EP2026811A1 (en) | 2009-02-25 |
BRPI0712022A2 (pt) | 2011-12-27 |
WO2007134828A1 (en) | 2007-11-29 |
MA30433B1 (fr) | 2009-05-04 |
KR20090008392A (ko) | 2009-01-21 |
IL195017A0 (en) | 2009-08-03 |
US8901134B2 (en) | 2014-12-02 |
MX2008014835A (es) | 2008-12-01 |
RU2008150619A (ru) | 2010-06-27 |
JP2009537580A (ja) | 2009-10-29 |
PE20080315A1 (es) | 2008-06-11 |
ECSP088902A (es) | 2008-12-30 |
CN101443013A (zh) | 2009-05-27 |
US20180125849A1 (en) | 2018-05-10 |
AU2007253615B2 (en) | 2011-06-23 |
ZA200809097B (en) | 2009-11-25 |
NO20084997L (no) | 2008-12-22 |
CA2650661A1 (en) | 2007-11-29 |
US20140051698A1 (en) | 2014-02-20 |
KR101106853B1 (ko) | 2012-01-19 |
AU2007253615A1 (en) | 2007-11-29 |
AR061057A1 (es) | 2008-07-30 |
CL2007001455A1 (es) | 2008-05-16 |
US20140235632A1 (en) | 2014-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR110051A2 (es) | Pirazolo[3,4-d]pirimidinas útiles para tratar trastornos respiratorios | |
AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
AR113818A2 (es) | Pirazolo-quinazolinas como inhibidores de proteína quinasa | |
PE20212302A1 (es) | Inhibidores de apol1 y sus metodos de uso | |
AR068511A1 (es) | Tetrahidro[1,4'] bipiridinil-2'-onas sustituidas, composiciones farmaceuticas que las contienen y usos de las mismas para tratar o prevenir trastornos del sistema nervioso central | |
AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
CL2020001919A1 (es) | Inhibidores de endonucleasa cap-dependientes. | |
AR049333A1 (es) | Azaindoles inhibidores de proteinquinasas rock y otras proteinas quinasas. composiciones farmaceuticas. | |
AR051026A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
AR048266A1 (es) | Compuesto de benzazepina, composicion farmaceutica que lo comprende y su uso para prepararla | |
AR065354A1 (es) | Derivados de 2-aminopirimidina, un metodo para su preparacion, una composicion farmaceutica que lo comprende y su uso en el tratamiento de enfermedades mediadas por el receptor de histamina h4. | |
AR090292A1 (es) | Compuestos basados en pirazolo[1,5-a]pirimidina, composiciones que los comprenden y metodos que los utilizan | |
AR070221A1 (es) | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. | |
AR074002A1 (es) | Pirazolo e imidazopiridinilpirimidinaminas como inhibidores de la tirosina kinasa (igr-ir) | |
AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
AR078786A1 (es) | Derivados de la cromenona | |
AR056265A1 (es) | N-aminometilensulfonamidas sustituidas, su preparacion y su uso como medicamentos | |
AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
EA200971115A1 (ru) | Новые ингибиторы обратной транскриптазы вич | |
CO6260074A2 (es) | Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa | |
AR081261A1 (es) | Metodos para tratar afecciones virales | |
AR072622A1 (es) | Derivados de imidazo[2,1-b][1,3,4]tiadiazol, composiciones farmaceuticas que los comprenden, metodo para prepararlos, y uso de los mismos para el tratamiento de tumores y otras enfermedades inducidas por quinasas | |
EA201101566A1 (ru) | Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ | |
AR060535A1 (es) | Pirido-piridazinonas y ftalazinonas como antagonistas duales de los receptores h1 y h3 de histamina | |
CU20090048A7 (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen |